Crescent Biopharma Inc. (CBIO)
CBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/0001628280-26-011983-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CBIO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001253689 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Cayman Islands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $10.8M |
| Net income | -$153.9M |
| Operating income | -$152.6M |
| Net margin | -1419.6% |
| Operating margin | -1407.5% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $213.2M |
| Total assets | $240.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 48.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $289.4M cash; operating cash flow -$20.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 38,895,442 (2026-11-11); 13,892,516 a year earlier; 64,393,294 three years earlier. 3y figure adjusted for split (1-for-100 overall). | Cover page 2026-11-11 |
| Reverse splits, 3 years | 1; latest 1-for-100 on 2025-06-16 | Source 2025-06-16 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-07-15 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-06-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $30.6M, sold $1.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $3.1M | -$37.7M | -$26.9M | $289.4M | No debt tags | $15.0M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $0 | -$24.8M | -$19.5M | $171.6M | No debt tags | $11.9M | 10-Q 2026-07-30 |
| Q1 2026 2026-03-31 | $1.0M | -$23.3M | -$8.9M | $189.2M | No debt tags | $11.9M | 10-Q 2026-04-29 |
| Q4 2025 2025-12-31 | $10.8M | -$23.3M | -$26.7M | $213.2M | No debt tags | $10.8M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $0 | -$24.6M | -$17.5M | $133.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $0 | -$21.8M | -$16.4M | $152.6M | No debt tags | Needs four quarters | 10-Q 2026-07-30 |
| Q1 2025 2025-03-31 | $0 | -$15.1M | -$10.9M | $22.4M | No debt tags | Needs four quarters | 10-Q 2026-04-29 |
| Q4 2024 2024-12-31 | Not filed | -$7.2M | -$3.7M | $34.8M | No debt tags | Needs four quarters | 10-K 2025-02-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-07-30 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 682 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.5% |
| 1 month | +9.6% |
| 3 months | -14.9% |
| Year to date | +19.3% |
| 1 year | +9.0% |
| From 52-week high | -47.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INDP | Indaptus Therapeutics Inc. | $3.45 | +8.83% | $529.9M |
| GYRE | Gyre Therapeutics Inc. | $4.39 | +1.86% | $506.3M |
| ZVRA | Zevra Therapeutics Inc. | $9.25 | +1.87% | $550.4M |
| EVO | Evotec SE | $1.56 | -1.27% | $555.0M |
| HELP | Helus Pharma Inc. | $7.67 | -13.53% | $560.4M |
| MNPR | Monopar Therapeutics Inc. | $71.97 | -0.04% | $487.7M |
| WVE | Wave Life Sciences Inc. | $2.87 | -8.31% | $566.0M |
| CAPR | Capricor Therapeutics Inc. | $8.30 | -12.91% | $482.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier